<DOC>
	<DOCNO>NCT02361216</DOCNO>
	<brief_summary>The objective trial investigate efficacy safety ingenol mebutate gel actinic keratosis apply large treatment area daily three consecutive day face , scalp chest .</brief_summary>
	<brief_title>Efficacy Safety Ingenol Mebutate Gel Actinic Keratosis Applied Large Area Face , Scalp Chest</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Subjects 5 20 clinically typical , visible discrete , actinic keratosis ( AKs ) nonhyperkeratotic nonhypertrophic AKs within select treatment area sundamaged skin either : The full face The full balding scalp A contiguous area approximately 250 cm2 chest Location treatment area ( full face , full balding scalp chest ) within 5 cm incompletely heal wound within 5 cm suspect basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) . Previously assign treatment clinical trial previously participate clinical trial LEO clinical programme ingenol mebutate gel large treatment area . Treatment ingenol mebutate gel select treatment area within last 12 month . Lesions treatment area : atypical clinical appearance ( e.g . cutaneous horn ) and/or , recalcitrant disease ( e.g. , respond cryotherapy two previous occasion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>